INTRODUCTION
The C1q assay assesses the ability of an antigen/ antibody complex to bind the first component of complement potentially (but not necessarily) leading to target cell killing. It marries the sensitivity and specificity of flow or Luminex solid phase assays with the functionally relevant capacity to fix complement to define antibodies of clinical significance to human leukocyte antigen (HLA) in solid organ transplantation. Since the first reports in 2011 showing high incidence of early rejection in pediatric hearts [1] , acute rejection and graft loss in pediatric and adult kidneys [2, 3] , and confirmed by a subsequent study of more than 1000 kidney recipients [4] , most reports have shown that C1q correlates significantly with risk of antibody-mediated rejection (AMR) and/or graft loss in kidneys. C1qþ donorspecific antibody (DSA) is more clinically relevant for outcome than IgGþ DSA alone especially when de novo DSA (dnDSA) arises posttransplant. Still, use of C1q to predict graft outcome remains controversial and some attribute its correlation with clinical outcomes to other reasons, such as IgG subclass or titer. Careful attention to report details is required to determine whether the data support the conclusions as we move toward finding the best means to predict outcome.
Technical issues
The original C1q assay [5] was far more sensitive than complement-dependent cytotoxicity (CDC) in picking up complement fixing antibody. The commercial assay is much less sensitive than the original C1q method [ Fig. 1 ] leading to false-negative, but not false-positive, results. Schaub et al. [34] showed that the addition of antihuman globulin to the test would significantly increase its sensitivity.
Based on more than 10 000 C1q tests, we have found that every individual has different background fluorescence in the test, some with high normalized mean fluorescence intensity (nMFI) values [Tyan, unpublished observations]. Consequently, it is not reliable to set a standard MFI cutoff for all. Prior reports have set values of 300, 500, and 1000 MFI as cutoffs with a mix of raw and nMFI values. In our experience, arranging the nMFI values from lowest to highest, finding the first increase of 300 MFI and adding 1000 to the lower MFI value at the break will yield an MFI threshold above which antibodies are clearly and reliably positive with major increases in MFI above that point. Those below the 300 MFI break are negative, and those in between are considered 'possible.' In contrast to published reports, C1q is also subject to prozone effects and serum treatment to eliminate the prozone can yield significantly different results.
CONTROVERSIES
There are three main controversies related to the C1q assay, namely: high IgG MFI values give the same information as C1q; IgG titer is the clinically relevant feature of the antibody and C1q results are only a function of the titer; and C1q positivity is a function of IgG subclass and the subclass can substitute for C1q.
C1q and IgG mean fluorescence intensity
Many reports have shown a correlation between C1q positivity with high IgG MFI values (threshold: 7000-10 000) and extrapolated that the C1q test is therefore not necessary. However, these same reports have shown that the relationship is not absolute because some IgG with low MFI can fix C1q whereas some with very high MFI do not, even when the serum is treated to eliminate any prozone [6] [7] [8] [9] 10 & ,11 && ]. We have observed C1qþ results with IgG MFI as low as 2000 [Tyan, unpublished observations]. Thus, it is necessary to actually do the C1q assay to be certain of the complement fixing status of any given antibody.
C1q and IgG titer
The lack of 1 : 1 correlation between IgG MFI and C1q positivity has led to the view that it is the IgG titer rather than the neat MFI that equates with C1q, especially given prozones in neat sera. Correlation between IgG and C1q improves whenever the sera are titered [6, 7, 12] showing titers between 1 : 16 and 1 : 32 by IgG equate to appearance of C1q reactivity; but C1qþ/IgG low outliers are routinely observed [6, 8] . However, in these studies, sera were only tested neat by C1q and no study to date has compared C1q to IgG at every dilution for every serum making it difficult to determine the precise correlation of C1q with titer or if it is the same for every serum/patient.
C1q and IgG subclass
IgG subclasses fix complement in the order of G3>G1>>G2>G4. Some have suggested that rather than test by C1q, determining the IgG subclass would reveal the complement fixing IgG antibodies. The rationale for doing four tests for subclass in place of one for C1q is unclear, as studies have shown that the presence of complement fixing subclasses does not correlate with C1q reactivity or graft outcome [13] . The only subclass that has been shown to have a significant impact on graft outcome is IgG3 [10 & ,14 & ] but C1q and IgG3 each have independent predictive value for graft outcome. Additionally, IgG subclass cannot be used to monitor patients being desensitized with intravenous immunoglobulin (IVIG) or other drugs containing human antibody (e.g, ATG) as these antibodies also contain IgG subclasses.
CLINICAL APPLICATION AND RELEVANCE OF C1q
The clinical relevance of C1q status for assessing risk for AMR and graft loss has been extensively studied
KEY POINTS
C1qþ antibody is significantly correlated with antibody-mediated rejection and graft loss.
IgG MFI of neat serum alone, independent of prozone or any other quality such as titer or subclass, is inadequate to predict graft outcome.
Parallel titers of C1q and IgG have not been performed and correlation between the two is unknown.
IgG3 and C3d together with C1q are all independent predictors of AMR and graft loss.
De novo C1qþ DSA is especially harmful and portends graft loss 1-2.5 years post detection.
in adult kidney patients both pretransplant and posttransplant with fewer studies in heart and pediatric kidney patients. Patient cohorts have been stratified according to whether they were unsensitized, sensitized or highly sensitized at transplant; developed de novo antibody; were desensitized; had early, late, or subclinical rejection; and/or experienced graft loss. Other methods have been compared with C1q to determine whether these yielded better information to help stratify risk. Serum treatment to remove prozone has varied widely or not been done.
PRETRANSPLANT
The relevance of pretransplant C1qþ DSA is variable. Arreola-Guerra, et al. [15 && ] reported that a negative AHG-CDC crossmatch (XM) with IgGþ DSA, C1qþ DSA predicts a positive flow XM (FXM) with an odds ratio (OR) ¼ 27. FXM positivity is highest when the IgG MFI is less than 5000. C1qþ DSA was the most specific (95.8%) and IgG MFI ¼ 2300 plus C1qþ DSA together the most sensitive (92%). They also found [ least 15 000 MFI (OR: 16.3 vs. 6.4, respectively) for predicting AMR. Multivariable logistic regression showed C1qþ DSA was a risk factor for AMR (OR ¼ 16.80, P ¼ 0.001) but high MFI DSAs were not. Six-year graft survival was also significantly lower in high MFI C1qþ DSA in comparison with C1qÀ, IgG high or low MFI DSA (38, 83 and 80%, respectively; P ¼ 0.001). There is only one prospective study comparing C1q pretransplant and posttransplant. Viglietti et al. [14 & ] found 31.8% patients had preformed C1qþ DSA at t 0 with 5-year graft survival of 45.8% in the C1qþ group compared with 92.1% in the C1qÀ group using EDTA-treated serum. IgG3 DSA status at t 0 was independently associated with graft survival and C1qþ IgG3 provided the best reclassification of risk for graft loss. On a practical note, Juhl et al. [18 && ], found only 2.2% positive prospective CDC XM in 1432 performed. Of those, 73.1% were C1qþ, leading them to suggest that by using C1q, CDC XM could be safely eliminated and replaced by VXM resulting in less shipment of donor material, shorter CIT, less DGF, and fewer false-positive XMs while not disqualifying highly sensitized patients. A single study of pretransplant allosensitization and outcomes in sensitized and unsensitized heart recipients [19] found no association of C1q with AMR, but the authors noted that a prospective negative CDC XM was required that likely eliminated any preformed C1qþ DSA patients. ] studied 62 unsensitized pediatric kidney recipients with clinically indicated biopsies and found 42% were DSAþ and 15% also C1qþ, independent of IgG MFI. Four-year graft survival for the DSAþ C1qþ group was 11% compared with 88% (DSAÀ; P < 0.001) and 82% (DSAþ C1qÀ; P ¼ 0.001), with a HR ¼ 6.4 for the DSAþ C1qþ group for chronic active AMR. None who lost their grafts were C1qÀ and 43% were C1qþ, though not necessarily C1qþ DSA, possibly due to adsorption of C1qþ DSA onto the graft. They suggest that C1qþ DSA at the time of an indication biopsy identifies a subgroup of pediatric patients with a markedly increased risk for subsequent graft loss. ] found C1qþ dnDSA independently associated with AMR and graft loss in univariate and multivariate analyses. IgG MFI of dnDSA failed to show any statistical association with any parameter tested. C1qþ DSA correlated with interstitial edema but not cg scores. C1qþ dnDSA and C1qþ MFI at time of first detection of DSA (2.7-3.8 years) had a significantly higher risk of AMR within the next year and in multivariate analysis an overall risk of AMR (HR ¼ 2.27) prompting them to suggest obtaining a biopsy at time of dnDSA detection. Wiebe et al. [23] showed C1qþ dnDSA had a specificity of 0.82 and a positive predictive value (PPV) of 0.83 for AMR and a significant correlation with graft loss (C1qþ 71%, C1qÀ 28%, P < 0.01) that became significant 3 years post dnDSA detection. C1q positivity correlated with tubulitis (P ¼ 0.02) and C4dþ staining (P ¼ 0.03). They found no correlation with sera titered between 1 : 16 and 1 : 1024 and tested by IgG even when using IgG MFI > 0 to assign a positive IgG. Despite these data, C1q results were discounted and outcomes attributed to noncompliance and clinical phenotypes that cannot be easily or reliably measured prospectively, do not translate into meaningful prognostic clinical tests and, therefore, are not useful for monitoring efficacy of intervention.
Lefaucheur et al. [10 & ] reported that C1qþ dnDSA in the first posttransplant year had a risk of 4.8 for graft loss and adverse pathology. Neither strong IgG MFI nor IgG subclass was predictive of C1q positivity, rather the best correlation was with multiple IgG subclasses combined. Cicciarelli et al. [13] studied C1q and IgG subclasses in C4dþ DSAþ kidney patients biopsied for cause more than 7 years posttransplant. Although there was a trend toward graft loss and possibly severity of rejection in C1qþ DSA patients, neither C1q nor subclass significantly correlated with AMR. Additionally, complement fixing subclasses that should have caused C1q to be positive did not and vice versa. Though C1q correlated best with AMR, they attributed results instead to C3d, which was not tested. C1qþ DSA correlated with IgG MFI > 12 000 and C4dþ leading them to conclude that C1q is simply a function of IgG MFI and subclass.
Yamamoto et al. [24 && ] reported that 40% of patients with dnDSA and a late biopsy have subclinical rejection. C1qþ dnDSA was an independent predictor of subclinical rejection. In contrast, Kauke et al. [25 & ] did not find an association between de novo C1qþ or C1qÀ DSA in 110 kidney recipients with acute rejection but found significantly diminished renal function in patients with C1qþ DSA.
Five-year allograft survival, when stratified according to dnDSA vs. non-DSA (nDSA) and C1q-binding status, significantly decreased from C1qÀ nDSA (93.5%; P ¼ 0.4860) to C1qþ nDSA (80.9%; P ¼ 0.0251) to C1qÀ DSA (76.9%; P ¼ 0.0012) to C1qþ DSA (59.7%, P < 0.0001) as compared with controls (90.7%), with C1qþ DSA having the highest risk for graft loss. They suggested that C1qþ de novo antibody, whether DSA or not, indicated a higher risk for graft failure. Eskandary et al. [26] studied complement fixing DSA in 86 DSAþ kidney patients with stable graft function; 51% had AMR on protocol biopsy. They reported significantly higher C1q MFI (but not C3d or C4d MFI) in AMRþ vs. AMRÀ patients (P ¼ 0.03). Among AMRÀ patients with focal C4d lesions C1q MFI levels were higher than in patients without lesions. Comoli et al. [27] reported dnDSA at median 3.6-year posttransplant in unsensitized pediatric kidney recipients (25 C1qþ, 9 C3dþ) . They concluded that C3d correlated better with graft loss than C1q; however, they noted that the statistical power was too low for multivariate analysis. They found no AMR-free graft survival if IgGþ/C1qþ/C3dþ DSA was present. As graft loss occurred about 2 years post dnDSA detection, they recommended treating when dnDSA was first detected since monitoring would be expensive. In a similar cohort stratified by early (less than 1 year) and late (more than 1 year) dnDSA detection, Cioni et al. [28] reported 47% AMRþ and 20% subsequent graft loss in the early group; 80% of which were C1qþ.
Interestingly, decreased graft survival was observed when C1qþ (but not IgG) antibody to denatured class I or class IþII antigen was present. This was associated with AMR and mixed rejection rather than CMR [29] .
Few recent studies exist in heart transplants. Frank et al. [30 & ] reported that 82% of EMB specimens taken at the time of graft dysfunction were C1qþ of which 56% were C4dþ. Only one C4dþ/ C1qÀ EMB was seen. No difference in graft failure was observed related to C1q status, perhaps due to selection bias as noted by the authors.
DESENSITIZATION
Different strategies for desensitization exist. As some therapeutic drugs raise the background in the tests making lowering of antibody difficult to measure (e.g. monitoring high dose IVIG desensitization by an IgG assay), monitoring methods need to be carefully selected.
Ramon et al. [31 & ] studied 30 kidney patients with biopsy-proven AMR and graft dysfunction. They showed that achieving C1qÀ DSA was significantly better than measuring 50% or more reduction in IgG MFI for predicting graft survival at 2 and 3 years post treatment (3 years, P ¼ 0.02) and had better specificity (0.8 vs. 0.55) and PPV (0.83 vs. 0.44) than measuring IgG MFI reduction. Class II antibodies are especially refractory to IgG MFI decreases of at least 50%. They noted that when the treatment cannot lower the DSA below the complement fixing threshold, the mechanism of injury cannot be controlled. Tambur et al. [32] studied MFI values of sera tested neat by IgG and C1q compared with serial dilutions by IgG in a mixed population of 40 kidney recipients desensitized by plasmapheresis and low-dose IVIG either pretransplant with relatively low levels of DSA or posttransplant with AMR. Assessing all SABþ antibodies and not DSA specifically, they concluded that titers were more informative than neat MFI values by IgG or C1q for tracking efficacy of the treatment. Unfortunately, sera were not all pretreated to remove prozones nor assessed at each dilution for C1q status to confirm whether there is a 1 : 1 correlation. No outcome data were reported. Schaefer et al. [33 & ] studied 80 presensitized kidney recipients (!85%) who had been desensitized by plasmapheresis and anti-CD20 therapy. Posttransplant, patients with C1qþ DSA had significantly higher rates of AMR and graft loss due to AMR when compared with those with C1qÀ or no DSA (86 vs. 33 vs. 0%, AMR) and (86 vs. 0 vs. 0%, graft loss), respectively. The positive predictive value for graft loss was 86%.
CONCLUSION
Knowing when to transplant, with which donor, when and how long to desensitize, and when to augment or discontinue augmented immunosuppression are goals shared by all. The majority of recent reports demonstrate that C1q is better correlated with AMR and graft loss than neat IgG MFI. Direct 1 : 1 titration comparisons of IgG and C1q are missing and no studies of outcomes based on titer stratification have been done. Such studies would be informative and worthwhile. Without such data, current literature suggests that C1q is more reliable for making choices. C1q is a discrete variable yielding a yes/no answer for complement fixation, whereas titer is not. The value of knowing the dilution at which the serum can no longer fix complement would be advantageous and perhaps allow transplant or discontinuation of desensitization at titers that could vary among individuals, especially in the posttransplant setting where the DSA is specifically known. Finally, C1q was never intended to be a standalone method for assessing clinical risk of rejection and/or graft failure. Combined data from C1q and IgG assays (e.g. MFI/subclass/titer) and/or other complement fixing assays (e.g. C3d) provide the most informative picture of individualized risk for the patient both before and after transplant.
